All In Biotech

Drug Trial Radar · NCT06611423

AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal Impairment

A Phase Ib, Double-blind, Placebo-controlled, Randomised Trial Investigating the Effect of AZD3427 on Renal Perfusion in HFrEF Patients With Renal Impairment Using Positron Emission Tomography (PET)

Last checked: Nov 19, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

10

Actual

Start

Oct 15, 2024

Primary completion

Aug 21, 2025

Study completion Aug 21, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
CTC Clinical Trial Consultants AB; Karolinska Institutet
First posted
Sep 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The present study is designed to test the effect of AZD3427 on renal perfusion in participants with heart failure and reduced eGFR (30 to 90 mL/min/1.73m2).

Conditions

  • Heart Failure With Reduced Ejection Fraction (HFrEF)
  • Renal Impairment

Interventions

  • AZD3427Biological

    AZD3427 SC injection to be prepared using AZD3427 diluent

  • AZD3427 PlaceboOther

    AZD3427 Placebo

  • DopamineDrug

    Dopamine Hydrochloride 50mg/5mL

  • Radiolabelled ligandOther

    Injection of radioligand for PET examinations

  • SalineOther

    Saline solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The volumetric fraction (%) of the renal cortex with increased perfusion from baseline to Day 8, compared to placebo.Time frame: Baseline to Day 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Solna, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.